• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Elevance Health Inc.

    3/27/26 4:21:47 PM ET
    $ELV
    Medical Specialities
    Health Care
    Get the next $ELV alert in real time by email
    DEFA14A 1 a2026_defa14a.htm DEFA14A a2026_defa14a
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant ☐ Filed by a party other than the Registrant CHECK THE APPROPRIATE BOX: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☑ Definitive Additional Materials ☐ Soliciting Material under §240.14a-12 Elevance Health, Inc. (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) PAYMENT OF FILING FEE (CHECK ALL BOXES THAT APPLY): ☑ No fee required ☐ Fee paid previously with preliminary materials ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11


     
    Step 1: Go to www.envisionreports.com/elv Step 2: Click on Cast Your Vote or Request Materials. Step 3: Follow the instructions on the screen to log in. www.envisionreports.com/elv Online Go to www.envisionreports.com/elv or scan the QR code — login details are located in the shaded bar below. Shareholder Meeting Notice 048HYC Important Notice Regarding the Availability of Proxy Materials for the Elevance Health Shareholder Meeting to be Held on May 13, 2026 Under Securities and Exchange Commission rules, you are receiving this notice that the proxy materials for the annual shareholders’ meeting are available on the internet. Follow the instructions below to view the materials and vote online or request a copy. The items to be voted on and instructions for participating in the annual meeting are on the reverse side. Your vote is important! This communication presents only an overview of the more complete proxy materials that are available to you on the internet. We encourage you to access and review all of the important information contained in the proxy materials before voting. The Notice of Annual Meeting of Shareholders, Proxy Statement and 2025 Annual Report on Form 10-K are available at: Obtaining a Copy of the Proxy Materials – If you want to receive a copy of the proxy materials, you must request one. There is no charge to you for requesting a copy. Please make your request as instructed on the reverse side on or before May 3, 2026 to facilitate timely delivery. 2 N O T Easy Online Access — View your proxy materials and vote. When you go online, you can also help the environment by consenting to receive electronic delivery of future materials. The Sample Company Step 4: Make your selections as instructed on each screen for your delivery preferences. Step 5: Vote your shares. If you hold shares in the Elevance Health Stock Fund pursuant to your participation in the 401(k) Plan or Puerto Rico Retirement Plan, votes submitted must be received by 11:59 p.m., Eastern Time, on May 8, 2026. MMMMMMMMMMMM M M M M M M M M M 0 0 0 0 0 1 MR A SAMPLE DESIGNATION (IF ANY) ADD 1 ADD 2 ADD 3 ADD 4 ADD 5 ADD 6 ENDORSEMENT_LINE______________ SACKPACK_____________ 1234 5678 9012 345 C 1234567890 C O Y MMMMMMM


     
    Here’s how to order a copy of the proxy materials and select delivery preferences: Current and future delivery requests can be submitted using the options below. If you request an email copy, you will receive an email with a link to the current meeting materials. PLEASE NOTE: You must use the number in the shaded bar on the reverse side when requesting a copy of the proxy materials. —  Internet – Go to www.envisionreports.com/elv. Click Cast Your Vote or Request Materials. — Phone – Call us free of charge at 1-866-641-4276. —  Email – Send an email to investorvote@computershare.com with “Proxy Materials Elevance Health” in the subject line. Include your full name and address, plus the number located in the shaded bar on the reverse side, and state that you want a paper copy of the meeting materials. To facilitate timely delivery, all requests for a paper copy of proxy materials must be received by May 3, 2026. Elevance Health’s Annual Meeting of Shareholders will be held on May 13, 2026 at 8:00 a.m. Eastern Time in a virtual format only, via live audio webcast at https://meetnow.global/MRG6YVV. To log in to the audio webcast as a shareholder, you must have the information that is printed in the shaded bar located on the reverse side of this form. Proposals to be voted on at the meeting are listed below along with the Board of Directors’ recommendations. The Board of Directors recommends a vote FOR each of the nominees listed in Proposal 1 and FOR Proposals 2 and 3. 1. Election of Directors: 01 - Gail K. Boudreaux 02 - Robert L. Dixon, Jr. 03 - Deanna D. Strable 2. Advisory Vote to Approve the Compensation of Our Named Executive Officers (“Say-on-Pay”). 3. Ratification of Ernst & Young LLP as Auditors for 2026. The Board of Directors recommends a vote AGAINST Proposal 4. 4. Shareholder Proposal Requesting an Independent Study on the Impact of Prohibiting Corporate Contributions to Partisan 527 Tax-Exempt Political Groups. In their discretion, the persons named as proxies are authorized to vote on any other business that may properly come before the 2026 Annual Meeting of Shareholders or any adjournment or postponement thereof. Shareholder Meeting Notice The Annual Meeting of Shareholders will be held in a virtual format only, via live audio webcast. Shareholders who participate in the virtual Annual Meeting of Shareholders may vote, submit questions and view the list of our shareholders of record during the Annual Meeting of Shareholders. Meeting Date and Time: May 13, 2026 at 8:00 a.m. Eastern Time Meeting Access: https://meetnow.global/MRG6YVV. The audio webcast is compatible with all common web browsers and may be viewed on mobile devices. Online access to the audio webcast will open 15 minutes prior to the start of the Annual Meeting of Shareholders to allow time to log in and test your device’s audio system. We encourage you to access the meeting in advance of the designated start time. To log in to the webcast as a shareholder of record or an associate shareholder, visit the meeting access link, click “Join Meeting Now” and provide your control number from the reverse side of this notice. You will be asked to accept Computershare’s Terms and Conditions. If you do not have internet access and want to listen to the Annual Meeting of Shareholders, please contact Elevance Health Shareholder Services at shareholder.services@elevancehealth.com or call (800) 985-0999 by May 11, 2026, for alternative access instructions. PLEASE NOTE – YOU CANNOT VOTE BY RETURNING THIS NOTICE. To vote your shares you must go online or request a paper copy of the proxy materials to receive a proxy card. If you wish to vote through the live webcast during the virtual Annual Meeting of Shareholders, please follow the directions above to log in to the webcast as a shareholder.


     
    Get the next $ELV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ELV

    DatePrice TargetRatingAnalyst
    5/20/2026$498.00Hold → Buy
    Deutsche Bank
    4/29/2026$435.00Neutral → Buy
    BofA Securities
    4/8/2026$345.00In-line
    Evercore ISI
    2/3/2026$358.00Outperform → Sector Perform
    RBC Capital Mkts
    1/8/2026$425.00Peer Perform → Outperform
    Wolfe Research
    12/19/2025$320.00Buy → Hold
    Deutsche Bank
    10/14/2025Neutral
    Goldman
    7/21/2025Buy → Hold
    Argus
    More analyst ratings

    $ELV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Peru Ramiro G bought $366,050 worth of shares (1,000 units at $366.05), increasing direct ownership by 10% to 10,908 units (SEC Form 4)

    4 - Elevance Health, Inc. (0001156039) (Issuer)

    7/17/26 3:04:55 PM ET
    $ELV
    Medical Specialities
    Health Care

    President and CEO Boudreaux Gail bought $1,002,230 worth of shares (2,725 units at $367.79), increasing direct ownership by 2% to 171,976 units (SEC Form 4)

    4 - Elevance Health, Inc. (0001156039) (Issuer)

    7/17/26 1:50:44 PM ET
    $ELV
    Medical Specialities
    Health Care

    Director Collis Steven H bought $869,520 worth of shares (3,000 units at $289.84), increasing direct ownership by 469% to 3,639 units (SEC Form 4)

    4 - Elevance Health, Inc. (0001156039) (Issuer)

    3/6/26 8:03:27 AM ET
    $ELV
    Medical Specialities
    Health Care

    $ELV
    SEC Filings

    View All

    SEC Form 10-Q filed by Elevance Health Inc.

    10-Q - Elevance Health, Inc. (0001156039) (Filer)

    7/15/26 11:27:18 AM ET
    $ELV
    Medical Specialities
    Health Care

    Elevance Health Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Elevance Health, Inc. (0001156039) (Filer)

    7/15/26 6:01:33 AM ET
    $ELV
    Medical Specialities
    Health Care

    SEC Form 11-K filed by Elevance Health Inc.

    11-K - Elevance Health, Inc. (0001156039) (Filer)

    6/17/26 1:58:21 PM ET
    $ELV
    Medical Specialities
    Health Care

    $ELV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Elevance Health Reports Second Quarter 2026 Results; Raises Full-Year Guidance

    2Q 2026 operating revenue of $49.8 billion, up 0.8% from 2Q 2025 2Q 2026 diluted EPS1 of $6.71 and adjusted diluted EPS2 of $7.45; results were supported by favorable benefit expense performance and an approximately $0.80 per share net below-the-line benefit FY 2026 diluted EPS1 guidance raised to at least $20.10; adjusted diluted EPS2 guidance raised to at least $27.00, reflecting strong second quarter operating results Accelerating targeted investments in capabilities that lower healthcare costs, simplify the member and provider experience, and strengthen Carelon's integrated solutions FY 2026 operating cash flow guidance raised to at least $6.0 billion Elevance Health, In

    7/15/26 6:00:00 AM ET
    $ELV
    Medical Specialities
    Health Care

    Elevance Health to Hold Conference Call and Webcast to Discuss Second Quarter 2026 Results on July 15, 2026

    Elevance Health (NYSE:ELV) will release second quarter 2026 financial results on July 15, 2026, at 6:00 a.m. Eastern Daylight Time ("EDT"). Management will review these results and its outlook during a conference call at 8:30 a.m. EDT that same morning. The conference call should be accessed at least 15 minutes prior to its start with the following numbers: 888-947-9963 - Access Code - 3972058 (Domestic) 312-470-0178 - Access Code - 3972058 (International) 800-391-9853 - No Access Code (Domestic Replay) 203-369-3269 - No Access Code (International Replay) The call will be available through a live webcast at www.elevancehealth.com under the "Investors" link. You may also acces

    7/6/26 4:30:00 PM ET
    $ELV
    Medical Specialities
    Health Care

    New Elevance Health Public Policy Institute Study Examines Payment Disputes for Planned Procedures Under the No Surprises Act

    Research finds arbitration awards for certain planned procedures are often far higher than typical in-network payment rates The No Surprises Act was created to protect patients from unexpected medical bills. While those patient protections are working, new research from the Elevance Health Public Policy Institute suggests that the law's payment dispute process is producing unexpected results for some planned medical procedures. The findings come as federal IDR volume has grown far beyond initial projections, raising concerns that a process intended as a limited payment-dispute backstop is increasingly contributing to higher out-of-network costs. The study examined more than 7,300 paym

    6/25/26 9:00:00 AM ET
    $ELV
    Medical Specialities
    Health Care

    $ELV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Elevance Health upgraded by Deutsche Bank with a new price target

    Deutsche Bank upgraded Elevance Health from Hold to Buy and set a new price target of $498.00

    5/20/26 8:03:29 AM ET
    $ELV
    Medical Specialities
    Health Care

    Elevance Health upgraded by BofA Securities with a new price target

    BofA Securities upgraded Elevance Health from Neutral to Buy and set a new price target of $435.00

    4/29/26 8:00:15 AM ET
    $ELV
    Medical Specialities
    Health Care

    Evercore ISI initiated coverage on Elevance Health with a new price target

    Evercore ISI initiated coverage of Elevance Health with a rating of In-line and set a new price target of $345.00

    4/8/26 8:36:16 AM ET
    $ELV
    Medical Specialities
    Health Care

    $ELV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Peru Ramiro G bought $366,050 worth of shares (1,000 units at $366.05), increasing direct ownership by 10% to 10,908 units (SEC Form 4)

    4 - Elevance Health, Inc. (0001156039) (Issuer)

    7/17/26 3:04:55 PM ET
    $ELV
    Medical Specialities
    Health Care

    President and CEO Boudreaux Gail bought $1,002,230 worth of shares (2,725 units at $367.79), increasing direct ownership by 2% to 171,976 units (SEC Form 4)

    4 - Elevance Health, Inc. (0001156039) (Issuer)

    7/17/26 1:50:44 PM ET
    $ELV
    Medical Specialities
    Health Care

    CAO & Controller Penczek Ronald W sold $148,766 worth of shares (369 units at $403.16), decreasing direct ownership by 9% to 3,740 units (SEC Form 4)

    4 - Elevance Health, Inc. (0001156039) (Issuer)

    6/15/26 4:10:45 PM ET
    $ELV
    Medical Specialities
    Health Care

    $ELV
    Leadership Updates

    Live Leadership Updates

    View All

    Elevance Health Announces Management Changes; CFO Mark Kaye to Expand Responsibilities to Include Carelon and Felicia Norwood to Lead Consolidated Health Benefits Organization

    Elevance Health, Inc. (NYSE:ELV) today announced management changes designed to simplify decision-making and strengthen execution across Carelon and Health Benefits. As part of these changes, Mark Kaye, Executive Vice President and Chief Financial Officer, will expand his responsibilities to include oversight of Carelon, the Company's healthcare services operations including pharmacy services, behavioral health, value-based care, and care delivery capabilities. Carelon plays a critical role in advancing the Company's strategy to lower the cost of care. Carelon's operating priorities and client commitments remain unchanged. Felicia Norwood, Executive Vice President and Chief Health Benef

    2/26/26 3:02:00 PM ET
    $ELV
    Medical Specialities
    Health Care

    Elevance Health Board Welcomes Amy Schulman as New Director, Reflecting Ongoing Commitment to Governance Excellence

    The board of directors of Elevance Health (NYSE:ELV) today announced the appointment of Amy Schulman, a recognized healthcare executive, investor, and governance leader, as an independent director, effective January 12, 2026. Schulman will serve on the Audit and Finance Committees, contributing deep expertise in healthcare innovation, regulatory strategy, and value creation across complex, global enterprises. This appointment reflects Elevance Health's ongoing board refreshment strategy to ensure diverse, independent, and future-focused leadership that aligns with the company's long-term strategy and stakeholders' priorities. "Amy's record of driving innovation, disciplined investment, an

    12/10/25 4:30:00 PM ET
    $ELV
    Medical Specialities
    Health Care

    Elevance Health Appoints Nathan Rich Vice President, Investor Relations

    Elevance Health (NYSE:ELV) announced today the appointment of Nathan Rich as Vice President, Investor Relations, effective November 11, 2024. In this role, Mr. Rich will lead Elevance Health's investor relations efforts, providing strategic leadership to support the company's growth initiatives and strengthen relationships within the investment community. He will also serve as a member of the company's executive leadership team and will report directly to Mark Kaye, Executive Vice President and Chief Financial Officer. Mr. Rich succeeds Stephen Tanal, who now serves as Chief Financial Officer for Elevance Health's Government Health Benefits business. "Nate brings nearly two decades of expe

    11/4/24 9:00:00 AM ET
    $ELV
    Medical Specialities
    Health Care

    $ELV
    Financials

    Live finance-specific insights

    View All

    Elevance Health Reports Second Quarter 2026 Results; Raises Full-Year Guidance

    2Q 2026 operating revenue of $49.8 billion, up 0.8% from 2Q 2025 2Q 2026 diluted EPS1 of $6.71 and adjusted diluted EPS2 of $7.45; results were supported by favorable benefit expense performance and an approximately $0.80 per share net below-the-line benefit FY 2026 diluted EPS1 guidance raised to at least $20.10; adjusted diluted EPS2 guidance raised to at least $27.00, reflecting strong second quarter operating results Accelerating targeted investments in capabilities that lower healthcare costs, simplify the member and provider experience, and strengthen Carelon's integrated solutions FY 2026 operating cash flow guidance raised to at least $6.0 billion Elevance Health, In

    7/15/26 6:00:00 AM ET
    $ELV
    Medical Specialities
    Health Care

    Elevance Health to Hold Conference Call and Webcast to Discuss Second Quarter 2026 Results on July 15, 2026

    Elevance Health (NYSE:ELV) will release second quarter 2026 financial results on July 15, 2026, at 6:00 a.m. Eastern Daylight Time ("EDT"). Management will review these results and its outlook during a conference call at 8:30 a.m. EDT that same morning. The conference call should be accessed at least 15 minutes prior to its start with the following numbers: 888-947-9963 - Access Code - 3972058 (Domestic) 312-470-0178 - Access Code - 3972058 (International) 800-391-9853 - No Access Code (Domestic Replay) 203-369-3269 - No Access Code (International Replay) The call will be available through a live webcast at www.elevancehealth.com under the "Investors" link. You may also acces

    7/6/26 4:30:00 PM ET
    $ELV
    Medical Specialities
    Health Care

    Elevance Health Reports First Quarter 2026 Results; Raises Full-Year Guidance

    1Q 2026 operating revenue of $49.5 billion, up 1.5% from 1Q 2025 1Q 2026 diluted EPS1 of $8.00; adjusted diluted EPS2 of $12.58 driven by strong operating results and ~$1 per share of non-recurring investment income FY 2026 diluted EPS1 guidance to be at least $19.85, including the Company's estimate of the financial impact for the CMS matter FY 2026 adjusted diluted EPS2 guidance raised to at least $26.75, supported by underlying business strength, actions to reduce medical costs, and increased visibility Reaffirm FY 2026 operating cash flow of at least $5.5 billion, inclusive of potential cash payments for the CMS matter Returned $1.5 billion of capital to shareholders in

    4/22/26 6:00:00 AM ET
    $ELV
    Medical Specialities
    Health Care

    $ELV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Elevance Health Inc.

    SC 13G/A - Elevance Health, Inc. (0001156039) (Subject)

    11/14/24 1:22:35 PM ET
    $ELV
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by Elevance Health Inc.

    SC 13G - Elevance Health, Inc. (0001156039) (Subject)

    2/14/24 10:02:59 AM ET
    $ELV
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by Elevance Health Inc.

    SC 13G - Elevance Health, Inc. (0001156039) (Subject)

    2/14/23 12:37:59 PM ET
    $ELV
    Medical Specialities
    Health Care